© Globe Newswire
18.10.2025
CELC
LISTED
NASDAQ
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
News Preview
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updates on the status of the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with and without palbociclib...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
CELC
LISTED
NASDAQ
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
News Preview
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated clinical results from the Phase 1 portion of a clinical trial evaluating gedatolisib in combination with Nubeqa® (darolutamide), an androgen receptor i...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
CELC
LISTED
NASDAQ
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
News Preview
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
17.10.2025
CTXR
LISTED
NASDAQ
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
News Preview
LD Micro Main Event XIX, October 19-21, 2025
2025 Maxim Growth Summit, October 22-23, 2025
The Think Equity Conference, October 30, 2025
CRANFORD, N.J., Oct....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ActuNews
17.10.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Oxurion Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC
Leuven, BELGIUM – October 17, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows...
Themefolio
Profiler
Peergroup
© ActuNews
17.10.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt aangepaste transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 17 oktober 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transparantiekennisgevin...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
FAGR
LISTED
EURONEXT
Fagron’s share buy-back program: Weekly update
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ORY
LISTED
BME
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
News Preview
MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the Phase III protocol to eva...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ZEAL
LISTED
CPH
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
News Preview
Company announcement – No. 22 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
IBAB
LISTED
EURONEXT
IBA opens the world of science and technology to secondary school girls
News Preview
Its Innovat’her event brought together female students to explore careers in STEM...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Pricing of Public Offering of Common Shares
News Preview
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
SLP
LISTED
NASDAQ
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation – SLP
News Preview
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.
So What: If you purchased Simulations P...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
16.10.2025
EHAB
LISTED
NYSE
Enhabit Home Health & Hospice Announces Date of 2025 Third Quarter Earnings Call
News Preview
Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its financial results for the third quarter ended Sept. 30, 2025, on Nov. 5, 2025, and host a webcast and conference call on Nov. 6, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes be...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2025
TFX
LISTED
NYSE
Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details
News Preview
WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Proposed Public Offering of Common Shares
News Preview
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of its common shares. atai expects to grant...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2025
ATAI
LISTED
NASDAQ
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
News Preview
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), and Beckley Psytech Limited (“Beckley Psytech”), who previously announced a planned strategic combination to create a global leader in transformative mental health therapies, today announced that the U.S. Food and Drug Administration...
Themefolio
Profiler
Peergroup
© ActuNews
16.10.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – October 16, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on October 15, 2025, from Atlas Special Oppor...
Themefolio
Profiler
Peergroup
© ActuNews
16.10.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 16 oktober 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transparantiekennisgevin...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
CU6
LISTED
ASX
Clarity signs copper-67 Supply Agreement with Nusano
News Preview
SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Supply Agreement for...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
CTXR
LISTED
NASDAQ
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
News Preview
EVERSANA
to provide integrated commercialization services,
enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy
CRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. (...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
TEM
LISTED
NASDAQ
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjuga...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
SECT_B
LISTED
STO
Sectra adds Smith+Nephew 3D templates to its orthopaedic solution--supporting wider adoption of digital surgical planning
News Preview
LINKÖPING, Sweden, Oct. 16, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra(STO: SECT B) has expanded its pre-operative planning solution for orthopaedic trauma cases with 3D templates from one of the world's leading medical equipment companies, Smith+Nephew. Extending the r...
Themefolio
Profiler
Peergroup
© EQS Newswire
16.10.2025
DIM
LISTED
EURONEXT
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
News Preview
Sartorius Stedim Biotech SA
/ Key word(s): 9 Month figures
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025 16-Oct-2025 / 07:00 CET/CEST
Aubagne, France | October 16, 2025
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
Sales revenue reaches 2,195 mi......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.10.2025
SRT3
LISTED
XETR
Sartorius schärft Prognose nach deutlich profitablem Umsatzwachstum in den ersten neun Monaten
News Preview
Göttingen, 16. Oktober 2025
Sartorius schärft Prognose nach deutlich profitablem Umsatzwachstum in den ersten neun Monaten
Konzernumsatz steigt in den ersten neun Monaten um 7,5 Prozent
Signifikanter Zuwachs im Wiederholgeschäft mit Verbrauchsmaterialien hält weiter an
Sparte Bioprocess Solutions wächst um rund 10 Prozent; Laborsparte erholt......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.10.2025
SRT3
LISTED
XETR
Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months
News Preview
Göttingen, Germany | October 16, 2025
Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months
Group sales revenue up 7.5 percent in the first nine months
Significant growth in recurring business with consumables continues
Bioprocess Solutions Division grows by around 10 percent, lab division rec......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.10.2025
FYB
LISTED
XETR
Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
News Preview
Press Release // October 16, 2025
Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) announces that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global c......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.10.2025
FYB
LISTED
XETR
Actor Pharmaceuticals und Megalabs werden Vermarktungspartner für Formycons Eylea®-Biosimilar FYB203 (Aflibercept) in Australien und Lateinamerika
News Preview
Pressemitteilung // 16. Oktober 2025
Actor Pharmaceuticals und Megalabs werden Vermarktungspartner für Formycons Eylea®-Biosimilar FYB203 (Aflibercept) in Australien und Lateinamerika
Planegg-Martinsried – Die Formycon AG (FWB: FYB, “Formycon”) gibt bekannt, dass die Klinge Biopharma GmbH (“Klinge”), Lizenznehmer und exklusiver Inhaber der welt......
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2025
BAVA
LISTED
CPH
The Board of Directors maintains its recommendation in supplementary statement in respect of the improved takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
16.10.2025
CLBX
LISTED
AIMX
ANGLE plc Announces Appointments: Interim CEO and Senior Board Advisor
News Preview
GUILFORD, SURREY, AL / ACCESS Newswire / October 16, 2025 / ANGLE plc (to be renamed CelLBxHealth plc) (AIM:AGL)(OTCQX:ANPCY), a world-leading circulating tumour cell (CTC) intelligence company with tests for use in research, drug development and clinical oncology, announces that it has strengthened its management team through two senior hires.Pete...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
NUTX
LISTED
NASDAQ
Nutex Health (NUTX) Faces Investor Lawsuit Over Alleged Revenue Inflation Scheme -- Hagens Berman
News Preview
Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to artificially boost its financial results. The litigation, filed in a Texas federal court, alleges that Nutex co...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Autolus Therapeutics Announces Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4)...
Themefolio
Profiler
Peergroup
© ActuNews
15.10.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 4 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 100.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1.
Leuven, BELGIUM– 15 oktober 2025 – 18u00 CET – Overeenkomstig artikel 15 van de...
Themefolio
Profiler
Peergroup
© ActuNews
15.10.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1].
Leuven, BELGIUM – 15 October, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports First Half 2025 Financial Results
News Preview
OSE Immunotherapeutics Reports First Half 2025 Financial Results...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF T...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
BAVA
LISTED
CPH
Consortium consisting of Nordic Capital and Permira increases offer price and extends offer period until 5 November 2025 in respect of the takeover offer to the shareholders of Bavarian Nordic
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
TEM
LISTED
NASDAQ
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany.
“We’re sharing research at ESMO Congress 2025, inclu...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2025 financial results and provide recent corporate updates on November 6, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).
Conference Call and Webcas...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
DFTX
LISTED
NASDAQ
MindMed Announces New Employee Inducement Grant
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to one newly hired non-executive employee consisting of an option to purchase 28,000 common shares of the Co...
Themefolio
Profiler
Peergroup
© ActuNews
14.10.2025
ALTHX
LISTED
EURONEXT
THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01
News Preview
THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01
THX Pharma (Theranexus) and Exeltis have reached a pivotal milestone, setting the stage for the regulatory submission of TX01 for Gaucher and Niemann-Pick type C diseases
Lyon, France – Madrid, Spain – October 14, 2025 – 6.30pm CEST &nd...
Themefolio
Profiler
Peergroup
© ActuNews
14.10.2025
ALTHX
LISTED
EURONEXT
THX PHARMA (THERANEXUS) ET EXELTIS FRANCHISSENT UNE ÉTAPE MAJEURE VERS LA COMMERCIALISATION DE TX01
News Preview
THX PHARMA (THERANEXUS) ET EXELTIS FRANCHISSENT UNE ÉTAPE MAJEURE VERS LA COMMERCIALISATION DE TX01
THX Pharma (Theranexus) et Exeltis ont atteint une étape clé, ouvrant la voie au dépôt du dossier réglementaire de TX01 pour les maladies de Gaucher et de Niemann-Pick de type C
Lyon, France – Madrid, Es...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
CU6
LISTED
ASX
Co-PSMA trial achieves primary endpoint
News Preview
SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Inve...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
TRAW
LISTED
NASDAQ
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
News Preview
Non-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
GMAB
LISTED
CPH
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
BIOA B
LISTED
STO
First patient treated with Leqembi® (lecanemab) in the Nordics
News Preview
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi has now been made available at a private clinic in Finland and that the first patient has started treatment. BioArctic copromotes Leqembi with its partner Eisai in the Nordic countries, and this ma...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ORNBV
LISTED
HEL
Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025
News Preview
ORION CORPORATION PRESS RELEASE 14 OCTOBER 2025 at 11.15 EEST ...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
BIOA B
LISTED
STO
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
News Preview
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease has been selected by TIME as one of the 'Best Inventions of 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
BIOA B
LISTED
STO
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
News Preview
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease has been selected by TIME as one of the 'Best Inventions of 2025...
Themefolio
Profiler
Peergroup
© ActuNews
13.10.2025
OXUR
LISTED
EURONEXT
Oxurion signs letter of intent for the contemplated acquisition of a CRO with strong complementarity to Axiodis
News Preview
Leuven, BELGIUM, October 13, 2025, 6:30 PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company based in Leuven, announces the signing of a letter of intent (LOI) to acquire a majority stake in a French Contract Research Organization (CRO) specialized in clinical development and regulatory affairs. This potential transaction is...
Themefolio
Profiler
Peergroup
© ActuNews
13.10.2025
OXUR
LISTED
EURONEXT
Oxurion signe une lettre d'intention pour l'acquisition projetée d'une CRO dotée d'une forte complémentarité avec Axiodis
News Preview
Louvain, BELGIQUE – 13 octobre 2025 – 18h30 – Oxurion NV (Euronext Bruxelles : OXUR), société biopharmaceutique basée à Louvain, annonce la signature d'une lettre d'intention (LOI) en vue de l'acquisition d'une participation majoritaire dans une Contract Research Organization (CRO) fran&...
Themefolio
Profiler
Peergroup
© ActuNews
13.10.2025
OXUR
LISTED
EURONEXT
Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een CRO die sterk complementair is aan Axiodis
News Preview
Leuven, BELGIË, 13 oktober 2025, 18u30 – Oxurion NV (Euronext Brussel: OXUR) kondigt vandaag de ondertekening aan van een intentieverklaring (Letter of Intent, LOI) met het oog op de overname van een meerderheidsbelang in een Franse Contract Research Organization (CRO), gespecialiseerd in klinische ontwikkeling en regelgevende aangelegen...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly known as ZL-1310, has been selected for an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets an...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
News Preview
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral p...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
UCB
LISTED
EURONEXT
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
News Preview
First published data from a multicenter retrospective chart review study to explore the safety and efficacy of pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 deficiency (TK2d).1
Neurology published results from a multicenter retrospective...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.10.2025
GXI
LISTED
XETR
FDA erteilt Zulassung für Lasix® ONYU* von SQ Innovation
News Preview
Gerresheimer: FDA erteilt Zulassung für Lasix® ONYU* von SQ Innovation
Innovatives Kombinationsprodukt aus Furosemid und On-Body Drug Delivery Device
Device konzipiert, entwickelt und hergestellt von Gerresheimer
Erste Produkte voraussichtlich bereits 2025 verfügbar
Düsseldorf, 13. Oktober 2025. Gerresheimer, innovativer System- und Lösungsanb......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.10.2025
GXI
LISTED
XETR
FDA grants Approval of SQ Innovation’s Lasix® ONYU*
News Preview
Gerresheimer: FDA grants Approval of SQ Innovation’s Lasix® ONYU*
Innovative combination product of furosemide and on-body device
Device designed, developed and manufactured by Gerresheimer
First products expected to be available already in 2025
Duesseldorf, Germany, October 13, 2025. Gerresheimer, an innovative system and solution provider and......
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
BAVA
LISTED
CPH
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.10.2025
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings
News Preview
MINNEAPOLIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today published Inspire V clinical outcomes data from its Singapore clinical...
Themefolio
Profiler
Peergroup
© ActuNews
09.10.2025
OXUR
LISTED
EURONEXT
Oxurion geeft een update met betrekking tot de strategie voor investering in digitale activa
News Preview
Leuven, BELGIË, 9 oktober 2025, 18u00 – Oxurion NV (Euronext Brussel: OXUR) kondigt vandaag aan dat de afronding van de nieuwe financiering gericht op investeringen in digitale activa (Bitcoin en Ethereum), waarvan de closing oorspronkelijk gepland was op 25 september 2025, nog in voorbereiding is.
De administratieve en compliance-gerela...
Themefolio
Profiler
Peergroup
© ActuNews
09.10.2025
OXUR
LISTED
EURONEXT
Oxurion annonce une mise à jour de sa stratégie d'investissement dans des actifs numériques
News Preview
Louvain, BELGIQUE, 9 octobre 2025, 18h00 - Oxurion NV (Euronext Bruxelles : OXUR), annonce aujourd'hui que la finalisation du nouveau financement visant à investir dans des actifs numériques (Bitcoin et Ethereum), dont le closing avait été annoncé pour le 25 septembre 2025, est toujours en cours.
Les ét...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
